Impact of KRAS mutation status on the efficacy of immunotherapy in lung cancer brain metastases

Immune checkpoint inhibitors (ICIs) have resulted in improved outcomes in non-small cell lung cancer (NSCLC) patients. However, data demonstrating the efficacy of ICIs in NSCLC brain metastases (NSCLCBM) is limited. We analyzed overall survival (OS) in patients with NSCLCBM treated with ICIs within...

Descripción completa

Detalles Bibliográficos
Autores principales: Lauko, Adam, Kotecha, Rupesh, Barnett, Addison, Li, Hong, Tatineni, Vineeth, Ali, Assad, Patil, Pradnya, Mohammadi, Alireza M., Chao, Samuel T., Murphy, Erin S., Angelov, Lilyana, Suh, John H., Barnett, Gene H., Pennell, Nathan A., Ahluwalia, Manmeet S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8438061/
https://www.ncbi.nlm.nih.gov/pubmed/34518623
http://dx.doi.org/10.1038/s41598-021-97566-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8438061/
https://www.ncbi.nlm.nih.gov/pubmed/34518623
http://dx.doi.org/10.1038/s41598-021-97566-z

Ejemplares similares